BCM
CBPO

Bayesian Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Bayesian Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,144
Closed -$245K – 614
2016
Q1 		$245K Buy
+2,144
New +$252K 0.23% 223

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bayesian Capital Management's CBPO Position: Q2 2016 in Review

Bayesian Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2016, closing a stake of 2,144 shares — an estimated $245K sold.

Bayesian Capital Management first reported a position in CBPO in Q1 2016 and held it in 1 quarter. The position peaked at $245K in Q1 2016. 138 funds tracked by Wall St. Rank hold CBPO as of Q2 2016.

  • Bayesian Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
  • Bayesian Capital Management sold 2,144 China Biologic Products Holdings, Inc. shares in Q2 2016, an estimated $245K.
  • Bayesian Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q1 2016 and held it in 1 quarter.
  • Bayesian Capital Management's China Biologic Products Holdings, Inc. position peaked at $245K in Q1 2016.
  • 138 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2016.

Based on Bayesian Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.